Shenzhen Inno Immunization

Shenzhen Inno Immunization is a clinical-stage biotechnology company headquartered in Shenzhen, China, dedicated to the development of innovative immune cell therapies. Established in 2016, the company focuses on T-cell receptor-engineered T-cell (TCR-T) and chimeric antigen receptor T-cell (CAR-T) therapies for the treatment of solid tumors and infectious diseases. A key differentiator of their platform is the ability to expand the population coverage of TCR-T therapies by targeting HLA-A2 supertypes, particularly for antigens like NY-ESO-1. The company operates a GMP-certified cell manufacturing facility and collaborates closely with the Shenzhen Inno Translational Medicine Research Institute. Its pipeline features several candidates in early clinical and preclinical development, including therapies for HPV-associated cancers and COVID-19. The company's research has been published in high-impact journals, demonstrating the efficacy of its TCR mimic nanobody-based CAR-T platform.